Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
222 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Clinical trials
553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (94)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03247010 | Bone Marrow Suppression and Recovery During Radionuclide Treatment | completed | — | 68 | Rigshospitalet, DenmarkOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT01942837 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | completed | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT04509557 |
| [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. |
| completed |
| Phase 1 |
| 30 |
| FutureChemINDUSTRY |
| 1 |
| Oct 20, 2022 |
| clinicaltrials |
| NCT02346526 | A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 22 | Massachusetts General HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT01517802 | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | completed | Phase 3 | 32 | Janssen Research & Development, LLCINDUSTRY | 7 | May 10, 2022 | clinicaltrials |
| NCT03071328 | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers | completed | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04862091 | Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 4, 2022 | clinicaltrials |
| NCT03101046 | Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic(TACTIK) | completed | Phase 2 | 40 | UNICANCEROTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT02207504 | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT04268628 | A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol(EXPLORE) | completed | — | 42 | Janssen-Cilag Farmaceutica Ltda.INDUSTRY | 1 | Jan 3, 2022 | clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT03136640 | ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 23 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT02346578 | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | completed | Phase 2 | 104 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | completed | Phase 1 | 502 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 30, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | completed | Phase 2 | 38 | Io TherapeuticsINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT03672396 | Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer | completed | N/A | 22 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT02111577 | Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer(VIABLE) | completed | Phase 3 | 1,182 | SOTIO a.s.INDUSTRY | 22 | Apr 6, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT01646684 | Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01634061 | Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | completed | Phase 1 | 43 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT01576172 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 159 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03774056 | A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. | completed | Phase 1 | 43 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03778047 | A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch | completed | Phase 1 | 10 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03419442 | Multi-academic Center Study of Xofigo Patients | completed | — | 150 | BayerINDUSTRY | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02471469 | Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response(ILUMINATE) | completed | — | 40 | Radboud University Medical CenterOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02228265 | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | completed | — | 41 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT01637402 | A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | completed | Phase 2 | 41 | Terence Friedlander, MDOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02125357 | Sequencing Abiraterone and Enzalutamide in mCRPC | completed | Phase 2 | 202 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT02991911 | A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer(MEDI3726) | completed | Phase 1 | 33 | MedImmune LLCINDUSTRY | 3 | Jan 18, 2020 | clinicaltrials |
| NCT02429193 | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA(BARRIER-P) | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT02066961 | A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer(ASPIRE-PCa) | completed | — | 1,533 | Astellas Pharma Global Development, Inc.INDUSTRY | 27 | Dec 20, 2019 | clinicaltrials |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00868595 | MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer | completed | Phase 1 | 18 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT02426333 | Optimizing Abiraterone Therapy(OPTIMUM) | completed | — | 56 | Radboud University Medical CenterOTHER | 1 | Sep 13, 2019 | clinicaltrials |
| NCT04056754 | Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer | completed | Phase 3 | 268 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01881867 | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01543776 | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | University of ChicagoOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT03927287 | Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer(FPSAR) | completed | — | 822 | Rabin Medical CenterOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT03030885 | Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT01487863 | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 69 | DendreonINDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01120470 | OGX-427 in Castration Resistant Prostate Cancer Patients | completed | Phase 2 | 74 | British Columbia Cancer AgencyOTHER | 2 | Feb 15, 2019 | clinicaltrials |
| NCT02012920 | A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 200 | Innocrin PharmaceuticalINDUSTRY | 4 | Feb 1, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Nov 9, 2022source: clinicaltrials